Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I respectfully disagree. With the companies plan to uplist I don't think they can be "quiet" for 19 days waiting for the D to drop off. I wouldn't be surprised to see PR's almost weekly.
Good to see SA covering AMBS.
AMBS has the potential catalysis to meet that challenge. It will simply take one institutional investor to see the value in ESS. I can honestly see AMBS announcing the closing of that acquisition, federal grant money being allocated to perform the Phase 2 trial and it's off to the races. The market cap could easily double from here on that alone.
Through in continued news on Eltro Phase 2 trail progression and much awaited LymPro data to be release at the AAIC conference in mid July and the PPS could reach Jason N valuation price.
These things come to fruition over the next 7.5 weeks. I believe GC is aware he needs to deliver now.
Amarantus Completes Capital Restructuring in Preparation for National Exchange Listing
Source: GlobeNewswire Inc.
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced it has completed its capital restructuring in preparation for a national exchange listing via a 1-for-150 reverse split of its common stock effective at the close of trading on Tuesday, June 9, 2015. Amarantus' common stock will trade on a split-adjusted basis under a new CUSIP number and temporary ticker symbol "AMBSD" beginning on Wednesday, June 10, 2015. After 20 days, the common stock will commence trading under the ticker symbol "AMBS."
"The streamlining of our capital structure will make Amarantus a much more attractive investment opportunity to the broader capital markets," said Gerald E. Commissiong, President & CEO of Amarantus. "As the Company begins its march towards a national exchange listing, we have a number of exciting milestones expected across each of our programs that we believe will drive value and raise the level of awareness of Amarantus within the scientific, medical, business and investment communities."
As a result of the stock split, every 150 shares of issued and outstanding common stock will be converted into 1 share of common stock. The Company's common stock will temporarily trade on the OTC QB under the symbol "AMBSD," for a period of 20 trading days after which time the symbol will revert back to AMBS. The temporary "D" at the end of the Company's stock symbol signifies that the reverse stock split has occurred. Following the reverse split, there will be approximately 7 million common shares outstanding.
All fractional shares created by the reverse stock split will be rounded to the nearest whole share. If the fraction created is one half or less, it will be rounded down to the nearest whole share. If the fraction is more than one half, it will be rounded up to the nearest whole share. Each shareholder will get at least one share.
The Company's transfer agent, VStock Transfer, LLC, will adjust its records to reflect each shareholder's post-split position. Share adjustments to physical stock certificates can be made upon surrender of the certificate to the transfer agent. Please contact VStock Transfer, LLC for further information at (212) 828-8436 or toll-free at (855)-9VSTOCK or by email at info@vstocktransfer.com.
Indeed the RS is tomorrow.
http://otce.finra.org/DLDividendsDistributionsSplit
Tweeted by GC this evening:
@G_Commish: @maglolos we expect the R/S to go into effect before Thursday. Thank you all for your patience as we waited for FINRA confirmation.
The same way they have for the past 2 years, financing. That is until the IPO, spin off and partnerships happen. A couple of which are only a couple months away.
Your point is irrelevant. Of course AMBS doesn't have cash, they are a pre-revenue biotech company.
Apology accepted and correct not many are willing to admit when they are wrong. I give you credit for doing so!
My guess on the RS is that either FINRA hasn't approved or the company thought this news would pop the SP and is waiting to enact it.
Lets try to be respectful here, we all make mistakes.
We all thought the RS would have happened by now, as did the GC.
You said "uplist" not RS. Lets be accurate here and not play silly games!
LOL get real. Here is the direct quote from the transcript.
With regard to the NASDAQ uplist, we anticipate that this will occur during the third quarter.
The CFO did not say that, not even logical.
lol the deal was worth 240 million period and was 21 years ago. Obviously additional money is spent to further develop but that doesn't change the value of the deal.
Please refer to the link GS1 so kindly posted for factual info.
Great link, thanks. Proves the point that none of the deals by themselves were for several billion or even have a potential value of being more than a billion.
AMBS will get there but it will take time.
Name them. And certainly being in the medical field you can point to some current companies not deals that happened over 20 years ago.
Amgen bought Synergen, who was developing GDNF, for $240 million back in 1994 which was $9.25 per share. So certainly that's not an example.
http://articles.latimes.com/1994-11-19/business/fi-64446_1_synergen-deal
Really. So you are saying a pre-revenue biotech with no Phase II trails started yet could be worth billions? Can you provide some examples?
The science at AMBS is good thus far. That is why it continues to be studied.
The science is already strong. With ESS and Gtown the key word is yet.
Kinda hard to buy at .04 with so many buying at .05+. I will take some at .04 if someone wants to sell to me down there. : )
Great post JP. Our time is near!
Correct about market cap but that is not what you were comparing in your "percentage". Your comment was about the fully diluted shares compared to the daily trading volume which means nothing because you add shares into the equation that aren't available for trading.
And not commenting on the rest of your post certainly doesn't mean I agree. Just didn't waste my time responding to all the misinformation.
What is interesting is that you included .36 billion shares in your "percentage" that couldn't possibly be traded for roughly 4 - 6 more months.
Good to see you check in here Red. I have shared many links from your DD that you posted elswhere. Thanks
Certainly the summer of transformation for AMBS. Looking forward to it!
Everyone believes him.
That's why the PPS didn't drop with the RS announcement.
I get the feeling by how GC talked on the call they are in talks to sell Lympro. He stated they may deal the diagnostic division in pieces so that could mean sell or partner.
If they can sell Lympro for nice up front money and keep a royalty payments I believe they will. GC wants to focus on therapeutic division.
You can read exactly what he said here:
http://seekingalpha.com/article/3216786-amarantus-biosciences-ambs-ceo-gerald-commissiong-hosts-business-update-conference-call-transcript?part=single
2 billion / 150 = 13,333,333
From the conf call:
Now as far as the business development update for LymPro, we made significant progress in the last several weeks. We’re under NDA with a number of parties, a number of parties are conducting due diligence on the data that we generated at ICON and are beginning now that the data -- we have the data under confidentiality are beginning to conduct due diligence on the LP-002 study and we’re hopeful to be able to make additional announcements regarding development from the business development area, in and around and following the AAIC meeting. I can’t say anything further beyond that but we’re very pleased with how the business development activity for LymPro is currently going.
Sure sounds like someone is interested in Lympro.
Here is the statement from the conference call transcript:
As far as Amarantus Diagnostics, as we’ve noted we’re preparing for an exit strategy to really unlock the value that we’ve created over the last several years from building this unit. The pipeline we all know in the diagnostics division is headed by LymPro in the diagnostic assay, blood test for Alzheimer’s disease that we’ve developed. We have submitted abstract to the Alzheimer’s Association International Conference for their late-breaking abstract session several weeks ago. Once we received from the clinical study that we’ve just completed LP-002 and we expect that we’ll soon be able to announce whether or not those abstracts have been accepted for public consumption, at meeting. We’re also show sponsor of AAIC. We made that decision obviously after we received the data and we’re very pleased that we’ll be a major part of the AAIC program in July. And we believe it’s going to provide us number of opportunities that we’re already starting to benefit from our business development activities.
Also GC stated in the conference call that they are under a NDA while companies are doing their DD on LymPro. They have this data and don't want it shared. Clearly meaning someone is interested in purchasing this asset....and they wouldn't be interested if the data was bad.
All your questions were answered in yesterday's conference call. I am sure anyone invested in AMBS was on the call or has since listened to it.
Seeking Alpha issued the transcript yesterday evening. Plenty of options to find answers beside on a message board.
The deal with Lonza will close. Gerald stated on the call yesterday that most of the monthly payments are going toward preparing ESS for the Phase 2 trial.
ESS is worth big money and closing on that deal as it is ready to begin the Phase 2 trial will be huge. They also talked about grant money this is available on closing the deal and additional grant money they will pursue after closing the deal.
This could be huge for AMBS. IMO
I still believe this will be a great investment. Those that continue to be negative about the science will soon look foolish. IMO
@JNapodano: These are the "success" stories for companies with late-stage CNS assets and why names like $CYNA and $AMBS offer such huge potential.
Agreed and with CLIA approval the DX becomes valued at many times higher than the IPO price.
IPO AMDX late Q3 then CLIA approvals by years end makes that division worth $XXX million...?!?!
Unless it's sold first.
The shelf registrations will allow AMBS to raise up to $150 million doing the IPO!
They are at the mercy of FINRA. I would be surprised if it didn't occur this week.
LPC and Dominion aren't stupid. Not to say they won't sell but with other Institutions looking to get on board and a move to the NASDAQ it's unlikely they look to sell.
But since it's a concern of yours when do their shares become unrestricted and how many do they have?
It was already filed so not sure what you mean by supposedly...